Toggle navigation
Home
Search
Services
Blog
Contact
About
Fish Technology to Localize a Prostate Cancer Gene
Call, Katherine M.
Oscient Pharmaceuticals Corporation, Waltham, MA, United States
Search 3 grants from Katherine Call
Search grants from Oscient Pharmaceuticals Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Publications
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer
Wnt11 signaling in stem cell survival and cardiac regeneration
Innovative translational medical nutrition training for non-physician scientists
Molecular Mechanisms of Photoreceptor Degeneration
III: Small: Collaborative Research: Finding and Exploiting Hierarchical Structure in Time Series Using Statistical Language Processing Methods
Recently added grants:
SCH: Active Learning for Medical Applications
Polymerase-mediated ultramutagenesis and carcinogenesis in mice
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines
Contributions of tumor molecular subtypes to prostate cancer racial disparities
Targeting CXCR2 axis in Pancreatic Cancer
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA067501-01
Application #
2111217
Study Section
Special Emphasis Panel (ZRG7-SSS-2 (22))
Project Start
1995-05-01
Project End
1996-09-30
Budget Start
1995-05-01
Budget End
1996-09-30
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Institution
Name
Oscient Pharmaceuticals Corporation
Department
Type
DUNS #
City
Waltham
State
MA
Country
United States
Zip Code
02453
Publications
Wang, Xi; Desai, Nishita; Hu, Ya-Ping et al.
(2008)
Mouse Fem1b interacts with the Nkx3.1 homeoprotein and is required for proper male secondary sexual development.
Dev Dyn 237:2963-72
Comments
Be the first to comment on Katherine Call's grant